Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05345821

An Analysis of Adverse Events and Satisfaction Outcomes of Women Who Underwent Primary and Secondary Breast Augmentation Using Silimed® Breast Implants With Smooth Surface

The study investigates the safety and performance of Silimed® brand smooth surface breast implants in women born with indication for primary and secondary (revision) augmentation to be followed up for 10 years. The safety of the smooth-surfaced Silimed® implant will be evaluated by estimating known and unexpected short-term and long-term risk/adverse event rates through patient reports of adverse events after implantation. The performance of using Silimed® brand smooth surface breast implants will be evaluated by evaluating satisfaction and quality of life after implantation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Fundação do ABC - Centro universitário FMABC

Santo André, São Paulo, 09060-870, Brazil

Location status: Recruiting

Location contact

David E Uip

CONTACT

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide written informed consent
  • Female at birth
  • Be 18 years of age or older
  • Have a complaint of hypomastia
  • Have an indication for breast augmentation with silicone implants
  • Ability to comply with the protocol throughout the follow-up period.

Exclusion criteria

  • Replacement of breast implants due to a complication
  • Breast reconstruction in at least one breast
  • Informed pregnancy or breastfeeding at the time of inclusion
  • Sequelae of mastopexy
  • Ptosis requiring mastopexy
  • Breast changes or lumps rated BI-RADS 3 or higher on preoperative ultrasound or mammograms
  • Advanced fibrocystic disease at the time of implantation
  • Neoplasia of any type not yet treated or undergoing treatment at the time of implantation, - Active infection not yet treated or undergoing treatment at any site at the time of implantation
  • Report or record of adverse reactions or intolerance to silicone prior to implantation
  • Report or record of immune diseases affecting the active or undergoing treatment (e.g. lupus erythematosus, discoid lupus, scleroderma, etc.) at the time of implantation
  • Signs of inflammation of the breast or implant site at the time of implantation
  • Increased risk of post-implantation complications -immediate surgical complications caused by illicit drug use or medication use
  • Having participated in another clinical trial within 6 months prior to implant placement
  • Any other condition which, based on the opinion of the investigator or designee, may prevent the provision of informed consent, make study participation unsafe, compromise protocol adherence, complicate the interpretation of study outcome data, or otherwise interfere with the achievement of study objectives

Treatment and study plan

Primary outcomes

  1. Expected Adverse Events

    Time frame: Every three years over the 10-year duration of the study

    Estimate the known short-term and long-term risk / adverse event rate for breast implant with smooth surface Silimed®

  2. Unexpected Adverse Events

    Time frame: Every three years over the 10-year duration of the study

    Estimate the unknown short-term and long-term risk / adverse event rate for breast implant with smooth surface Silimed®

Secondary outcomes

  1. Patient's Satisfaction in Relation to Aesthetic Result

    Time frame: Every three years over the 10-year duration of the study

    Estimate the performance of Silimed® breast implant with smooth surface through the satisfaction of the patient regarding the aesthetic result after breast augmentation. The assessment of patient's satisfaction will be done by means of a likert scale, where the following satisfaction options can be selected: 1 = definitely satisfied, 2 = satisfied, 3 = slightly satisfied, 4 = slightly dissatisfied and 5 = definitely unsatisfied.

  2. Patient's Satisfaction in General

    Time frame: Every three years over the 10-year duration of the study

    Estimate the performance of Silimed® breast implants with smooth surface after breast augmentation by means of a questionnaire, the Breast Self-Assessment Questionnaire (BEQ-Brazil), which consist of 55 questions related to satisfaction and comfort with the overall appearance of the breasts.

  3. Evaluator's Satisfaction in Relation to Aesthetic Result

    Time frame: Every three years over the 10-year duration of the study

    Estimate the performance of Silimed® breast implant with smooth surface througt the satisfaction of the evaluator regarding the aesthetic result after patient's breast augmentation. The assessment of evaluator's satisfaction will be done by means of a likert scale, where the following satisfaction options can be selected: 1 = definitely satisfied, 2 /= satisfied, 3= slightly satisfied, 4 = slightly dissatisfied and 5 = definitely unsatisfied.

  4. Patient's Quality of Life

    Time frame: Every three years over the 10-year duration of the study

    Estimate the performance of Silimed® breast implant with smooth surface through the quality of life of the patient after breast augmentation. The assessment of patient's quality of life will be done by means of the Rosemberg Global Self-Esteem Scale, in order to evaluate the overall self-esteem of the sample.

Study contacts

Contact information is provided by the study sponsor or research team.

Julia Maria V Roberto

CONTACT

[email protected]

+55212784 - 2772

Ludmila C Donato

CONTACT

[email protected]

+552198399-0573 ext. 2184-2771

Sponsors and collaborators

Lead sponsor

Silimed Industria de Implantes Ltda

Industry

Collaborators

  • Centro Universitário Saúde ABC

Registry information

Official study title

Post-market Monitoring and Control of Safety and Efficacy of Silimed® Breast Implants With Smooth Surface (STEPS S)

Acronym: STEPS S

Important dates

Study start
2022
Primary completion
2036
Study completion
2036
First posted
Apr 26, 2022
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.